Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass

Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.

[1]  A. Wittinghofer,et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.

[2]  T. Hanafusa,et al.  Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. , 1996, The Journal of clinical investigation.

[3]  P. Halban,et al.  Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14 , 2008, Diabetes.

[4]  J. Bluestone,et al.  Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. , 2007, Endocrinology.

[5]  N. Marrion,et al.  A novel lipid‐anchored A‐kinase Anchoring Protein facilitates cAMP‐responsive membrane events , 1998, The EMBO journal.

[6]  Thomas C. Südhof,et al.  Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion , 1997, Nature.

[7]  J. Bos,et al.  Epac-selective cAMP Analog 8-pCPT-2′-O-Me-cAMP as a Stimulus for Ca2+-induced Ca2+ Release and Exocytosis in Pancreatic β-Cells* , 2003, The Journal of Biological Chemistry.

[8]  S. Takasawa,et al.  Generation of Nicotinic Acid Adenine Dinucleotide Phosphate and Cyclic ADP-Ribose by Glucagon-Like Peptide-1 Evokes Ca2+ Signal That Is Essential for Insulin Secretion in Mouse Pancreatic Islets , 2008, Diabetes.

[9]  J. Holst,et al.  Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 , 1998, Pflügers Archiv.

[10]  C. Deacon,et al.  The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. , 2002, American journal of physiology. Endocrinology and metabolism.

[11]  M. Prentki,et al.  Glucagon-Like Peptide-1 Induced Signaling and Insulin Secretion Do Not Drive Fuel and Energy Metabolism in Primary Rodent Pancreatic β-Cells , 2009, PloS one.

[12]  Meng Chen,et al.  Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. , 2006, Biochemical and biophysical research communications.

[13]  G. Waeber,et al.  Exendin-4 Protects β-Cells From Interleukin-1β–Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway , 2008, Diabetes.

[14]  Thomas C. Südhof,et al.  Phosphorylation of RIM1α by PKA Triggers Presynaptic Long-Term Potentiation at Cerebellar Parallel Fiber Synapses , 2003, Cell.

[15]  M. Permutt,et al.  Genetic Deficiency of Glycogen Synthase Kinase-3β Corrects Diabetes in Mouse Models of Insulin Resistance , 2008, PLoS biology.

[16]  S. Pugazhenthi,et al.  Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients , 2010, Diabetologia.

[17]  M. Dolz,et al.  cAMP-secretion coupling is impaired in diabetic GK/Par rat β-cells: a defect counteracted by GLP-1. , 2011, American journal of physiology. Endocrinology and metabolism.

[18]  S. Dry,et al.  Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes , 2009, Diabetes.

[19]  M. Prentki,et al.  Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor , 2003 .

[20]  P. MacDonald,et al.  Antagonism of Rat β-Cell Voltage-dependent K+ Currents by Exendin 4 Requires Dual Activation of the cAMP/Protein Kinase A and Phosphatidylinositol 3-Kinase Signaling Pathways* , 2003, Journal of Biological Chemistry.

[21]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[22]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Bos,et al.  cAMP sensor Epac as a determinant of ATP‐sensitive potassium channel activity in human pancreatic β cells and rat INS‐1 cells , 2006, The Journal of physiology.

[24]  J. Scott,et al.  Targeted protein kinase A and PP-2B regulate insulin secretion through reversible phosphorylation. , 2001, Endocrinology.

[25]  J. Rømer,et al.  Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  M. Dolz,et al.  The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes? , 2009, Molecular and Cellular Endocrinology.

[27]  P. Brubaker,et al.  Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice , 2002, Diabetologia.

[28]  M. Hussain,et al.  Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. , 2002, Endocrinology.

[29]  Ana D. Lopez,et al.  A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth. , 2000, The Journal of clinical endocrinology and metabolism.

[30]  T. Shibasaki,et al.  Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis. , 2004, Diabetes.

[31]  D. Hill,et al.  Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. , 2006, Endocrinology.

[32]  M. Hussain,et al.  Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. , 2000, Diabetes.

[33]  SyedRizwanudden Ahmad,et al.  Exenatide and rare adverse events. , 2008, The New England journal of medicine.

[34]  D. Dore,et al.  Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. , 2009, Current medical research and opinion.

[35]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[36]  N. Welsh,et al.  Control of Insulin mRNA Stability in Rat Pancreatic Islets , 2002, The Journal of Biological Chemistry.

[37]  B. Friedrichsen,et al.  Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways , 2006 .

[38]  James D. Johnson,et al.  Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1) , 2006, Proceedings of the National Academy of Sciences.

[39]  M. Solimena,et al.  cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. , 2006, Cell metabolism.

[40]  Bernard Thorens,et al.  Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor Expression* , 2010, The Journal of Biological Chemistry.

[41]  Yazhou Li,et al.  β-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1 , 2005 .

[42]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[43]  N. Noguchi,et al.  CD38 Disruption Impairs Glucose-induced Increases in Cyclic ADP-ribose, [Ca2+] i , and Insulin Secretion* , 1999, The Journal of Biological Chemistry.

[44]  H. Ellingsgaard,et al.  Islet Inflammation in Type 2 Diabetes , 2008, Diabetes Care.

[45]  B. Yusta,et al.  GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress , 2006 .

[46]  Y. Kido,et al.  The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. , 2002, The Journal of clinical investigation.

[47]  J. Egan,et al.  GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells , 2003, Diabetes/metabolism research and reviews.

[48]  A M Graybiel,et al.  A family of cAMP-binding proteins that directly activate Rap1. , 1998, Science.

[49]  K. Prasadan,et al.  Cross-talk between Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling Is Essential for Exendin-4-induced Insulin-positive Differentiation of AR42J Cells* , 2005, Journal of Biological Chemistry.

[50]  D. Drucker,et al.  Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. , 2004, Endocrinology.

[51]  N. Yamamoto,et al.  Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies , 2007 .

[52]  S. Dry,et al.  Pancreatic duct replication is increased with obesity and type 2 diabetes in humans , 2009, Diabetologia.

[53]  M. Prentki,et al.  Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation , 2001 .

[54]  D. Rhie,et al.  Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element. , 2006, The Journal of endocrinology.

[55]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[56]  David D. Dore,et al.  Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide , 2009, Current medical research and opinion.

[57]  D. Drucker,et al.  Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice , 2009, Diabetes.

[58]  J. Gromada,et al.  Sulfonylurea Receptor Type 1 Knock-out Mice Have Intact Feeding-stimulated Insulin Secretion despite Marked Impairment in Their Response to Glucose* , 2002, The Journal of Biological Chemistry.

[59]  B. Portha,et al.  Glucagon-like peptide-1 ( 7 – 36 )-amide confers glucose sensitivity to previously glucose-incompetent â-cells in diabetic rats : in vivo and in vitro studies , 1997 .

[60]  S. Dry,et al.  Beneficial Endocrine but adverse Exocrine effects of Sitagliptin in the HIP rat model of Type 2 Diabetes, interactions with Metformin. , 2009 .

[61]  P. Butler,et al.  Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes , 2006, Diabetologia.

[62]  Scott D Covey,et al.  A Switch From Prohormone Convertase (PC)-2 to PC1/3 Expression in Transplanted α-Cells Is Accompanied by Differential Processing of Proglucagon and Improved Glucose Homeostasis in Mice , 2007, Diabetes.

[63]  John Calvin Reed,et al.  cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2 , 2003 .

[64]  J. Olefsky,et al.  β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells , 2008, Proceedings of the National Academy of Sciences.

[65]  D. Hörsch,et al.  Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. , 2002, The Journal of endocrinology.

[66]  S. Sollott,et al.  Glucagon‐like peptide‐1 does not mediate amylase release from AR42J cells , 1999, Journal of cellular physiology.

[67]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[68]  Ana D. Lopez,et al.  Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. , 2002, The Journal of clinical endocrinology and metabolism.

[69]  S. Bonner-Weir,et al.  GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts , 2006 .

[70]  Min Chen,et al.  β cell-specific deficiency of the stimulatory G protein α-subunit Gsα leads to reduced β cell mass and insulin-deficient diabetes , 2007, Proceedings of the National Academy of Sciences.

[71]  W. Catterall,et al.  β-Adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  D. Doudet,et al.  Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation , 2009, Diabetes.

[73]  G. Rutter,et al.  Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. , 2003, The Biochemical journal.

[74]  U. Boggi,et al.  Effects of exendin‐4 on islets from type 2 diabetes patients , 2008, Diabetes, obesity & metabolism.

[75]  L. Langeberg,et al.  Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Causes Pancreatic Duodenal Homeobox-1 Protein Translocation from the Cytoplasm to the Nucleus of Pancreatic β-Cells by a Cyclic Adenosine Monophosphate/Protein Kinase A-Dependent Mechanism. , 2001, Endocrinology.

[77]  R. Robertson.  Successful islet transplantation for patients with diabetes--fact or fantasy? , 2000, The New England journal of medicine.

[78]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[79]  D. Accili,et al.  Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic β-Cell Mass , 2006, Diabetes.

[80]  E. Hooghe-Peters,et al.  Interplay of nutrients and hormones in the regulation of insulin release. , 1985, Endocrinology.

[81]  P. Light,et al.  Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. , 2002, Molecular endocrinology.

[82]  Nils Brose,et al.  Functional Interaction of the Active Zone Proteins Munc13-1 and RIM1 in Synaptic Vesicle Priming , 2001, Neuron.

[83]  C. Wright,et al.  Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. , 2001, Diabetes.

[84]  J. Egan,et al.  Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. , 1999, Endocrinology.

[85]  H. Ohlsson,et al.  IPF1, a homeodomain‐containing transactivator of the insulin gene. , 1993, The EMBO journal.

[86]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[87]  B. Portha,et al.  Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. , 1997, The Journal of endocrinology.

[88]  R. Rizza,et al.  Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans , 2006, Diabetologia.

[89]  M. Prentki,et al.  Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells , 1999, Diabetologia.

[90]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[91]  M. Blandino-Rosano,et al.  Decrease in {beta}-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of Exendin-4. , 2010, Endocrinology.

[92]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[93]  I. Shimomura,et al.  Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes , 2007, Diabetologia.

[94]  J. Egan,et al.  The Role of Incretins in Glucose Homeostasis and Diabetes Treatment , 2008, Pharmacological Reviews.

[95]  M. Nakashima,et al.  Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. , 2000, The Journal of clinical investigation.

[96]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[97]  D. D’Alessio,et al.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. , 2008, Endocrine reviews.

[98]  A. Yamataka,et al.  Synergistic Endocrine Induction by GLP-1 and TGF-β in the Developing Pancreas , 2005 .

[99]  J. Habener,et al.  Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation* , 2008, Journal of Biological Chemistry.

[100]  L. Sheu,et al.  Interaction Between Munc13-1 and RIM Is Critical for Glucagon-Like Peptide-1–Mediated Rescue of Exocytotic Defects in Munc13-1–Deficient Pancreatic β-Cells , 2007, Diabetes.

[101]  D. Stoffers,et al.  Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. , 2003, Diabetes.

[102]  D. Bulchandani,et al.  Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas , 2009, Diabetologia.

[103]  T. Shibasaki,et al.  Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. , 2002, The Journal of biological chemistry.

[104]  Involvement of PDX-1 in activation of human insulin gene transcription. , 2006, The Journal of endocrinology.

[105]  J. Bryan,et al.  cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. , 2002, Diabetes.

[106]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[107]  Yasuhiro Sunaga,et al.  cAMP-GEFII is a direct target of cAMP in regulated exocytosis , 2000, Nature Cell Biology.

[108]  Jie Zhou,et al.  Exendin‐4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX‐1 and HNF3β transcription factors , 2002, Journal of cellular physiology.

[109]  M. Prentki,et al.  Glucagon-like peptide-1 prevents beta cell glucolipotoxicity , 2004, Diabetologia.